May 02, 2019 / 12:30PM GMT
Operator
Welcome to the Acorda Therapeutics First Quarter 2019 Update. (Operator Instructions) Please be advised that this call is being taped at the company's request. I will now introduce your host for today's call, Felicia Vonella, Vice President of Investor Relations at Acorda. Please go ahead.
Felicia Vonella - Acorda Therapeutics, Inc. - Executive Director of IR
Thank you, Christa, and good morning, everyone. Before we begin this morning, let me remind you that our presentation will contain forward-looking statements. Detailed disclosures can be found in our SEC filings, which are public, and we encourage you to refer to those filings.
I will now pass the call over to our CEO, Ron Cohen.
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Good morning, everyone. Thanks for joining us. By wide margin, the most important highlight of the first quarter was our commercial launch of INBRIJA, with drug in the channel as of February 28. INBRIJA is the first and only FDA approved inhaled
Q1 2019 Acorda Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot